-
公开(公告)号:US20140200223A1
公开(公告)日:2014-07-17
申请号:US14132877
申请日:2013-12-18
申请人: Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian Mckeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
发明人: Salvacion Cacatian , David A. Claremon , Lawrence Wayne Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian Mckeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
IPC分类号: C07D271/12 , C07D239/70 , C07D403/06 , C07D498/10 , C07D417/06 , C07D405/06 , C07D413/04 , C07D233/46
CPC分类号: C07D271/12 , C07D233/46 , C07D235/02 , C07D239/70 , C07D277/60 , C07D279/08 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D487/10 , C07D491/10 , C07D493/20 , C07D495/10 , C07D498/10 , C07D513/10
摘要: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
摘要翻译: 本发明涉及由以下结构式表示的化合物或其药学上可接受的盐。 还描述了化合物的药物组合物和使用方法。
-
公开(公告)号:US08673899B2
公开(公告)日:2014-03-18
申请号:US13347784
申请日:2012-01-11
申请人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Wei Zhao
发明人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Wei Zhao
IPC分类号: C07D413/10 , C07D413/14 , A61K31/5355
CPC分类号: C07D413/10 , C07D413/14
摘要: This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
摘要翻译: 本发明涉及可用于治疗性治疗的式Ik,Im1,Im2,Im5,In1,In2,In5,Io1,Io2,Io5,Ip1,Ip3,其药学上可接受的盐及其药物组合物的新型化合物 的与哺乳动物中的11beta-HSD1的调节或抑制相关的疾病。 本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇产生或抑制细胞中可的松转化为皮质醇的方法。
-
公开(公告)号:US08633212B2
公开(公告)日:2014-01-21
申请号:US12723137
申请日:2010-03-12
申请人: Salvacion Cacatian , David A. Claremon , Lawrence W. Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian McKeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
发明人: Salvacion Cacatian , David A. Claremon , Lawrence W. Dillard , Klaus Fuchs , Niklas Heine , Lanqi Jia , Katerina Leftheris , Brian McKeever , Angel Morales-Ramos , Suresh B. Singh , Shankar Venkatraman , Guosheng Wu , Zhongren Wu , Zhenrong Xu , Jing Yuan , Yajun Zheng
IPC分类号: A61K31/405 , A61K31/415 , A61K31/41 , A61K31/40 , C07D237/00 , C07D271/10 , C07D487/10 , C07D209/54
CPC分类号: C07D271/12 , C07D233/46 , C07D235/02 , C07D239/70 , C07D277/60 , C07D279/08 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D417/10 , C07D487/10 , C07D491/10 , C07D493/20 , C07D495/10 , C07D498/10 , C07D513/10
摘要: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.
摘要翻译: 本发明涉及由以下结构式表示的化合物或其药学上可接受的盐。 还描述了化合物的药物组合物和使用方法。
-
公开(公告)号:US08569292B2
公开(公告)日:2013-10-29
申请号:US12990306
申请日:2009-04-30
申请人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Frank Himmelsbach , Matthias Eckhardt , Wei Zhao
发明人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Zhenrong Xu , Yuanjie Ye , Suresh B. Singh , Salvacion Cacatian , Frank Himmelsbach , Matthias Eckhardt , Wei Zhao
IPC分类号: C07D413/10 , C07D413/14 , A61K31/5355
CPC分类号: C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14
摘要: This invention relates to novel compounds of the Formula I, Ik, Iq1-21, Ir1-21, Is1-21, It1-7, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
摘要翻译: 本发明涉及式I,Ik,Iq1-21,Ir1-21,Is1-21,It1-7,其药学上可接受的盐及其药物组合物的新型化合物,其可用于治疗与 哺乳动物中11β-HSD1的调节或抑制。 本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇产生或抑制细胞中可的松转化为皮质醇的方法。
-
公开(公告)号:US08455521B2
公开(公告)日:2013-06-04
申请号:US12802142
申请日:2010-05-28
申请人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty , Jean-Pierre Wery
发明人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty , Jean-Pierre Wery
IPC分类号: C07D417/04 , C07D409/06 , C07D405/06 , C07D401/06 , C07D417/06 , C07D265/30 , C07D211/22 , C07D211/26 , A61K31/5377 , A61K31/5375 , A61K31/445 , A61K31/4525 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545
CPC分类号: C07D417/06 , C07C233/40 , C07C235/40 , C07C235/42 , C07C271/20 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/22 , C07D211/56 , C07D401/06 , C07D405/06 , C07D405/12 , C07D409/06 , C07F7/081 , C07F7/0812
摘要: Diaminoalkanes of below Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity: They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.
摘要翻译: 现已发现以下式I的二氨基烷烃是口服活性的并与天冬氨酸蛋白酶结合以抑制其活性:它们可用于治疗或改善与升高的天冬氨酸蛋白酶活性水平相关的疾病。 本发明还涉及在有需要的受试者中使用式I化合物来改善或治疗天冬氨酸蛋白酶相关病症的方法,包括向所述受试者施用有效量的式I化合物。
-
公开(公告)号:US20130096108A1
公开(公告)日:2013-04-18
申请号:US13646031
申请日:2012-10-05
申请人: Frank Himmelsbach , David A. Claremon , Linghang Zhuang , Katerina Leftheris , Zhenrong Xu , Colin M. Tice
发明人: Frank Himmelsbach , David A. Claremon , Linghang Zhuang , Katerina Leftheris , Zhenrong Xu , Colin M. Tice
IPC分类号: C07D413/10 , C07D413/14
CPC分类号: C07D413/10 , C07D413/14
摘要: Disclosed is a compound represented by Formula (Im1): or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Also disclosed are pharmaceutical compositions comprising the compound of Formula (Im1) or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof and methods of inhibiting 11β-HSD1 activity comprising the step of administering to a mammal in need of such treatment an effective amount of a compound of Formula (Im1), or a pharmaceutically acceptable salt, monohydrate, enantiomer or diastereomer thereof. Values for the variables in Formula (Im1) are defined herein.
摘要翻译: 公开了由式(Im1)表示的化合物或其药学上可接受的盐,一水合物,对映体或非对映体。 还公开了包含式(Im1)化合物或其药学上可接受的盐,一水合物,对映异构体或非对映体的药物组合物和抑制11beta-HSD1活性的方法,其包括向需要这种治疗的哺乳动物施用有效量的 式(Im1)的化合物或其药学上可接受的盐,一水合物,对映体或非对映异构体。 公式(Im1)中变量的值在此定义。
-
公开(公告)号:US08242290B2
公开(公告)日:2012-08-14
申请号:US12678003
申请日:2008-09-17
IPC分类号: C07D309/04 , C07D309/06
CPC分类号: C07D309/04 , C07D309/06 , Y02P20/55
摘要: Disclosed is a process for the preparation of a tetrahydropyran-di-amine represented by Structural Formula (I): wherein R1 is H or alkyl and E is H or an amine protecting group.
摘要翻译: 公开了由结构式(I)表示的四氢吡喃二胺的制备方法:其中R1是H或烷基,E是H或胺保护基。
-
公开(公告)号:US08242111B2
公开(公告)日:2012-08-14
申请号:US12990309
申请日:2009-04-30
申请人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Yuanjie Ye , Suresh B. Singh
发明人: David A. Claremon , Linghang Zhuang , Katerina Leftheris , Colin M. Tice , Yuanjie Ye , Suresh B. Singh
IPC分类号: C07D417/14 , C07D413/14 , A61K31/5355
CPC分类号: C07D413/14 , C07D417/14
摘要: This invention relates to novel compounds of a structural formula selected from: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals, e.g., diabetes mellitus and obesity. Values for the variables in the structural formulas are provided herein. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell.
摘要翻译: 本发明涉及结构式的新化合物,其选自:其药学上可接受的盐及其药物组合物,其可用于治疗哺乳动物例如糖尿病中调节或抑制11β-HSD1相关疾病 和肥胖。 本文提供了结构式中变量的值。 本发明进一步涉及新化合物的药物组合物及其用于减少或控制细胞中皮质醇产生或抑制细胞中可的松转化为皮质醇的方法。
-
公开(公告)号:US08198453B2
公开(公告)日:2012-06-12
申请号:US12311012
申请日:2007-09-18
申请人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Lanqi Jia , Patrick T. Flaherty
发明人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Lanqi Jia , Patrick T. Flaherty
IPC分类号: C07D405/12 , A61K31/453
CPC分类号: C07D309/04 , C07D405/12
摘要: The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.
摘要翻译: 本发明涉及由以下结构式(I)表示的天冬氨酸蛋白酶抑制剂或其药学上可接受的盐。 本发明还涉及包含结构式(I)的天冬氨酸蛋白酶抑制剂的药物组合物。 还公开了在有需要的受试者中拮抗一种或多种天冬氨酸蛋白酶的方法,以及使用这些天冬氨酸蛋白酶抑制剂治疗受试者天冬氨酸蛋白酶介导的病症的方法。
-
公开(公告)号:US07872028B2
公开(公告)日:2011-01-18
申请号:US12225985
申请日:2007-04-05
申请人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty
发明人: John J. Baldwin , David A. Claremon , Colin M. Tice , Salvacion Cacatian , Lawrence W. Dillard , Alexey V. Ishchenko , Jing Yuan , Zhenrong Xu , Gerard McGeehan , Wei Zhao , Robert D. Simpson , Suresh B. Singh , Patrick T. Flaherty
IPC分类号: C07D211/22 , A61K31/445
CPC分类号: C07D211/22 , C07D207/08 , C07D265/30 , C07D413/12
摘要: Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated. levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use of the diaminopropanols in ameliorating or treating renin related disorders in a subject in need thereof.
摘要翻译: 描述其二氨基丙醇是口服活性的并且结合肾素以抑制其活性。 它们可用于治疗或改善与升高相关的疾病。 肾素活性水平或治疗天冬氨酸蛋白酶介导的病症。 还描述了在有需要的受试者中使用二氨基丙醇来改善或治疗肾素相关疾病的方法。
-
-
-
-
-
-
-
-
-